B-intervention	0	9	Tamoxifen
O	10	13	for
O	14	17	the
O	18	28	prevention
O	29	31	of
O	32	38	breast
O	39	45	cancer
O	45	46	:
O	47	54	current
O	55	61	status
O	62	64	of
O	65	68	the
O	69	77	National
O	78	86	Surgical
O	87	95	Adjuvant
O	96	102	Breast
O	103	106	and
O	107	112	Bowel
O	113	120	Project
O	121	122	P
O	122	123	-
O	123	124	1
O	125	130	study
O	130	131	.

O	132	139	Initial
O	140	148	findings
O	149	153	from
O	154	157	the
O	158	166	National
O	167	175	Surgical
O	176	184	Adjuvant
O	185	191	Breast
O	192	195	and
O	196	201	Bowel
O	202	209	Project
O	210	216	Breast
O	217	223	Cancer
O	224	234	Prevention
O	235	240	Trial
O	241	242	(
O	242	243	P
O	243	244	-
O	244	245	1
O	245	246	)
O	247	259	demonstrated
O	260	264	that
O	265	274	tamoxifen
O	275	282	reduced
O	283	286	the
O	287	291	risk
O	292	294	of
O	295	303	estrogen
O	304	312	receptor
O	312	313	-
O	313	321	positive
O	322	328	tumors
O	329	332	and
O	333	345	osteoporotic
O	346	355	fractures
O	356	358	in
B-eligibility	359	364	women
I-eligibility	365	367	at
I-eligibility	368	377	increased
I-eligibility	378	382	risk
I-eligibility	383	386	for
I-eligibility	387	393	breast
I-eligibility	394	400	cancer
O	400	401	.

O	402	406	Side
O	407	414	effects
O	415	417	of
O	418	425	varying
O	426	434	clinical
O	435	447	significance
O	448	452	were
O	453	461	observed
O	461	462	.

O	463	466	The
O	467	472	trial
O	473	476	was
O	477	486	unblinded
O	487	494	because
O	495	497	of
O	498	501	the
O	502	510	positive
O	511	518	results
O	518	519	,
O	520	523	and
O	524	530	follow
O	530	531	-
O	531	533	up
O	534	543	continued
O	543	544	.

O	545	549	This
O	550	556	report
O	557	564	updates
O	565	568	our
O	569	576	initial
O	577	585	findings
O	585	586	.

O	587	592	Women
O	593	594	(
O	594	595	n
O	596	597	=
B-total-participants	598	600	13
I-total-participants	600	601	,
I-total-participants	601	604	388
O	604	605	)
O	606	610	were
O	611	619	randomly
O	620	628	assigned
O	629	631	to
O	632	639	receive
B-control	640	647	placebo
O	648	650	or
O	651	660	tamoxifen
O	661	664	for
O	665	666	5
O	667	672	years
O	672	673	.

O	674	679	Rates
O	680	682	of
O	683	689	breast
O	690	696	cancer
O	697	700	and
O	701	706	other
O	707	713	events
O	714	718	were
O	719	727	compared
O	728	730	by
O	731	734	the
O	735	738	use
O	739	741	of
O	742	746	risk
O	747	753	ratios
O	754	755	(
O	755	758	RRs
O	758	759	)
O	760	763	and
O	764	766	95
O	766	767	%
O	768	778	confidence
O	779	788	intervals
O	789	790	(
O	790	793	CIs
O	793	794	)
O	794	795	.

O	796	805	Estimates
O	806	808	of
O	809	812	the
O	813	816	net
O	817	824	benefit
O	825	829	from
O	830	831	5
O	832	837	years
O	838	840	of
O	841	850	tamoxifen
O	851	858	therapy
O	859	863	were
O	864	872	compared
O	873	875	by
O	876	879	age
O	879	880	,
O	881	885	race
O	885	886	,
O	887	890	and
O	891	901	categories
O	902	904	of
O	905	914	predicted
O	915	921	breast
O	922	928	cancer
O	929	933	risk
O	933	934	.

O	935	946	Statistical
O	947	952	tests
O	953	957	were
O	958	961	two
O	961	962	-
O	962	967	sided
O	967	968	.

O	969	974	After
O	975	976	7
O	977	982	years
O	983	985	of
O	986	992	follow
O	992	993	-
O	993	995	up
O	995	996	,
O	997	1000	the
B-outcome	1001	1011	cumulative
I-outcome	1012	1016	rate
I-outcome	1017	1019	of
I-outcome	1020	1028	invasive
I-outcome	1029	1035	breast
I-outcome	1036	1042	cancer
O	1043	1046	was
O	1047	1054	reduced
O	1055	1059	from
B-cv-bin-abs	1060	1062	42
I-cv-bin-abs	1062	1063	.
I-cv-bin-abs	1063	1064	5
O	1065	1068	per
B-control-participants	1069	1073	1000
O	1074	1079	women
O	1080	1082	in
O	1083	1086	the
O	1087	1094	placebo
O	1095	1100	group
O	1101	1103	to
B-iv-bin-abs	1104	1106	24
I-iv-bin-abs	1106	1107	.
I-iv-bin-abs	1107	1108	8
O	1109	1112	per
B-intervention-participants	1113	1117	1000
O	1118	1123	women
O	1124	1126	in
O	1127	1130	the
O	1131	1140	tamoxifen
O	1141	1146	group
O	1147	1148	(
O	1148	1150	RR
O	1151	1152	=
O	1153	1154	0
O	1154	1155	.
O	1155	1157	57
O	1157	1158	,
O	1159	1161	95
O	1161	1162	%
O	1163	1165	CI
O	1166	1167	=
O	1168	1169	0
O	1169	1170	.
O	1170	1172	46
O	1173	1175	to
O	1176	1177	0
O	1177	1178	.
O	1178	1180	70
O	1180	1181	)
O	1182	1185	and
O	1186	1189	the
B-outcome	1190	1200	cumulative
I-outcome	1201	1205	rate
I-outcome	1206	1208	of
I-outcome	1209	1220	noninvasive
I-outcome	1221	1227	breast
I-outcome	1228	1234	cancer
O	1235	1238	was
O	1239	1246	reduced
O	1247	1251	from
B-cv-bin-abs	1252	1254	15
I-cv-bin-abs	1254	1255	.
I-cv-bin-abs	1255	1256	8
O	1257	1260	per
B-control-participants	1261	1265	1000
O	1266	1271	women
O	1272	1274	in
O	1275	1278	the
O	1279	1286	placebo
O	1287	1292	group
O	1293	1295	to
B-iv-bin-abs	1296	1298	10
I-iv-bin-abs	1298	1299	.
I-iv-bin-abs	1299	1300	2
O	1301	1304	per
B-intervention-participants	1305	1309	1000
O	1310	1315	women
O	1316	1318	in
O	1319	1322	the
O	1323	1332	tamoxifen
O	1333	1338	group
O	1339	1340	(
O	1340	1342	RR
O	1343	1344	=
O	1345	1346	0
O	1346	1347	.
O	1347	1349	63
O	1349	1350	,
O	1351	1353	95
O	1353	1354	%
O	1355	1357	CI
O	1358	1359	=
O	1360	1361	0
O	1361	1362	.
O	1362	1364	45
O	1365	1367	to
O	1368	1369	0
O	1369	1370	.
O	1370	1372	89
O	1372	1373	)
O	1373	1374	.

O	1375	1380	These
O	1381	1391	reductions
O	1392	1396	were
O	1397	1404	similar
O	1405	1407	to
O	1408	1413	those
O	1414	1418	seen
O	1419	1421	in
O	1422	1425	the
O	1426	1433	initial
O	1434	1440	report
O	1440	1441	.

O	1442	1451	Tamoxifen
O	1452	1455	led
O	1456	1458	to
O	1459	1460	a
B-iv-bin-percent	1461	1463	32
I-iv-bin-percent	1463	1464	%
B-outcome	1465	1474	reduction
I-outcome	1475	1477	in
I-outcome	1478	1490	osteoporotic
I-outcome	1491	1500	fractures
O	1501	1502	(
O	1502	1504	RR
O	1505	1506	=
O	1507	1508	0
O	1508	1509	.
O	1509	1511	68
O	1511	1512	,
O	1513	1515	95
O	1515	1516	%
O	1517	1519	CI
O	1520	1521	=
O	1522	1523	0
O	1523	1524	.
O	1524	1526	51
O	1527	1529	to
O	1530	1531	0
O	1531	1532	.
O	1532	1534	92
O	1534	1535	)
O	1535	1536	.

O	1537	1545	Relative
O	1546	1551	risks
O	1552	1554	of
B-outcome	1555	1561	stroke
O	1561	1562	,
B-outcome	1563	1567	deep
I-outcome	1567	1568	-
I-outcome	1568	1572	vein
I-outcome	1573	1583	thrombosis
O	1583	1584	,
O	1585	1588	and
B-outcome	1589	1598	cataracts
O	1599	1600	(
O	1600	1605	which
O	1606	1615	increased
O	1616	1620	with
O	1621	1630	tamoxifen
O	1630	1631	)
O	1632	1635	and
O	1636	1638	of
B-outcome	1639	1647	ischemic
I-outcome	1648	1653	heart
I-outcome	1654	1661	disease
O	1662	1665	and
B-outcome	1666	1671	death
O	1672	1673	(
O	1673	1678	which
O	1679	1683	were
O	1684	1687	not
O	1688	1695	changed
O	1696	1700	with
O	1701	1710	tamoxifen
O	1710	1711	)
O	1712	1716	were
O	1717	1721	also
O	1722	1729	similar
O	1730	1732	to
O	1733	1738	those
O	1739	1748	initially
O	1749	1757	reported
O	1757	1758	.

B-outcome	1759	1764	Risks
I-outcome	1765	1767	of
I-outcome	1768	1777	pulmonary
I-outcome	1778	1786	embolism
O	1787	1791	were
O	1792	1805	approximately
O	1806	1808	11
O	1808	1809	%
O	1810	1815	lower
O	1816	1820	than
O	1821	1823	in
O	1824	1827	the
O	1828	1836	original
O	1837	1843	report
O	1843	1844	,
O	1845	1848	and
O	1849	1854	risks
O	1855	1857	of
O	1858	1869	endometrial
O	1870	1876	cancer
O	1877	1881	were
O	1882	1887	about
O	1888	1890	29
O	1890	1891	%
O	1892	1898	higher
O	1898	1899	,
O	1900	1903	but
O	1904	1909	these
O	1910	1921	differences
O	1922	1926	were
O	1927	1930	not
O	1931	1944	statistically
O	1945	1956	significant
O	1956	1957	.

O	1958	1961	The
O	1962	1965	net
O	1966	1973	benefit
O	1974	1982	achieved
O	1983	1987	with
O	1988	1997	tamoxifen
O	1998	2004	varied
O	2005	2014	according
O	2015	2017	to
O	2018	2021	age
O	2021	2022	,
O	2023	2027	race
O	2027	2028	,
O	2029	2032	and
O	2033	2038	level
O	2039	2041	of
O	2042	2048	breast
O	2049	2055	cancer
O	2056	2060	risk
O	2060	2061	.

O	2062	2069	Despite
O	2070	2073	the
O	2074	2083	potential
O	2084	2088	bias
O	2089	2095	caused
O	2096	2098	by
O	2099	2102	the
O	2103	2113	unblinding
O	2114	2116	of
O	2117	2120	the
O	2121	2122	P
O	2122	2123	-
O	2123	2124	1
O	2125	2130	trial
O	2130	2131	,
O	2132	2135	the
O	2136	2146	magnitudes
O	2147	2149	of
O	2150	2153	all
O	2154	2164	beneficial
O	2165	2168	and
O	2169	2180	undesirable
O	2181	2190	treatment
O	2191	2198	effects
O	2199	2201	of
O	2202	2211	tamoxifen
O	2212	2216	were
O	2217	2224	similar
O	2225	2227	to
O	2228	2233	those
O	2234	2243	initially
O	2244	2252	reported
O	2252	2253	,
O	2254	2258	with
O	2259	2266	notable
O	2267	2277	reductions
O	2278	2280	in
O	2281	2287	breast
O	2288	2294	cancer
O	2295	2298	and
O	2299	2308	increased
O	2309	2314	risks
O	2315	2317	of
O	2318	2332	thromboembolic
O	2333	2339	events
O	2340	2343	and
O	2344	2355	endometrial
O	2356	2362	cancer
O	2362	2363	.

O	2364	2371	Readily
O	2372	2384	identifiable
O	2385	2392	subsets
O	2393	2395	of
O	2396	2407	individuals
O	2408	2418	comprising
O	2419	2420	2
O	2420	2421	.
O	2421	2422	5
O	2423	2430	million
O	2431	2436	women
O	2437	2442	could
O	2443	2449	derive
O	2450	2451	a
O	2452	2455	net
O	2456	2463	benefit
O	2464	2468	from
O	2469	2472	the
O	2473	2477	drug
O	2477	2478	.
